RxDoctor Payments Data

Jean Sheridan-Young

Nurse Practitioner · Jacksonville, FLNPI 1285177832

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $20,644 of the $21,802 with a category attached, or 94.7%. AbbVie accounts for 99.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $10,702 and has fallen 99.9% since, to $15 in 2025. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,802in general payments, 2019–2025

Across 56 payments — averaging $389.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$22K
  • Biohaven Pharmaceutical Holding Company Ltd.$102
  • Boston Scientific$15
  • Impel Pharmaceuticals Inc.$12

What the payments were for

  • Speaking & faculty fees$20,64495%
  • Food & beverage$1,1475%
  • Education$120%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,802 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$225,978
Medicare patients
366
Services billed
6,823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina46$59,829
UbrelvyUbrogepant16$28,951
Aimovig AutoinjectorErenumab-Aooe29$22,020
Emgality PenGalcanezumab-Gnlm27$17,741
Sumatriptan Succinate29$1,548
Gabapentin48$520
Methocarbamol35$401
Cyclobenzaprine Hcl14$177
Topiramate17$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy$21,674$88,78062 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →